{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:26:15Z","timestamp":1790270775012,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Rheumatoid arthritis (RA) and Sj\u00f6gren\u2019s syndrome (SS) are systemic autoimmune conditions. SS frequently occurs associated with RA. In patients with RA, those with SS exhibit a higher disease burden, increased disease activity, and more complex comorbidities compared with those without SS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>We report a 54-year-old female patient who was previously diagnosed with early-stage RA less than 1 year ago. She was subsequently confirmed to have SS associated with RA. Additionally, she developed multiple autoimmune comorbidities, including autoimmune hepatitis and type 1 renal tubular acidosis. The patient resisted various treatments, including immunosuppressive drugs, disease-modifying antirheumatic drugs, and anti-inflammatory small-molecule drugs. This was evidenced by poor DA28 responses, persistent laboratory abnormalities, and ongoing symptoms and signs. Finally, she responded well to Telitacicept, a BLyS\/APRIL dual inhibitor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Even in the early stage, multiple autoimmune comorbidities can exhibit high levels of disease activity and may not respond to conventional therapies. Telitacicept, the first dual inhibitor of BLyS\/APRIL, has the potential to provide significant efficacy and safety for RA patients who also have overlapping SS and other autoimmune diseases that do not respond to standard treatments. The limitations included the absence of a liver biopsy and the short follow-up period.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1558059","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:04:07Z","timestamp":1742281447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: A refractory unusual tetrad of overlap syndrome involving rheumatoid arthritis, Sj\u00f6gren\u2019s syndrome, autoimmune hepatitis, and type 1 renal tubular acidosis, successfully treated with a BLyS\/APRIL dual inhibitor"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05004-8","article-title":"Prevalence of Sj\u00f6gren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry","volume":"39","author":"Harrold","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.19723\/j.issn.1671-167X.2022.06.002","article-title":"A cross-sectional study on the clinical phenotypes of rheumatoid arthritis","volume":"54","author":"Cai","year":"2022","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.562101","article-title":"Biomarkers and diagnostic testing for renal disease in sjogren's syndrome","volume":"11","author":"Ramponi","year":"2020","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","author":"Kay","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210448","article-title":"Standardisation of labial salivary gland histopathology in clinical trials in primary Sj\u00f6gren's syndrome","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 american college of rheumatology\/european league against rheumatism classification criteria for primary sj\u00f6gren's syndrome: A consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01587-5","article-title":"Renal tubular acidosis and management strategies: A narrative review","volume":"38","author":"Palmer","year":"2021","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01032-y","article-title":"Distal renal tubular acidosis: a systematic approach from diagnosis to treatment","volume":"34","author":"Giglio","year":"2021","journal-title":"J Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180392","article-title":"Primary versus secondary sj\u00f6gren syndrome: is it time to reconsider these terms","volume":"46","author":"Mavragani","year":"2019","journal-title":"J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu400","article-title":"Clinical characteristics of RA patients with secondary SS and association with joint damage","volume":"54","author":"Brown","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298447","article-title":"Potential mechanisms and drug prediction of Rheumatoid Arthritis and primary Sj\u00f6gren's Syndrome: A public databases-based study","volume":"19","author":"Wu","year":"2024","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2024.10410","article-title":"Association of focus score and extraglandular involvement in Sj\u00f6gren's syndrome: A study on antinuclear antibodies and minor salivary gland pathology","volume":"39","author":"Erg\u00fcn","year":"2024","journal-title":"Arch Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9195157","DOI":"10.1155\/2023\/9195157","article-title":"Clinical significance of different profiles of anti-ro antibodies in connective tissue diseases","volume":"2023","author":"Yang","year":"2023","journal-title":"J Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i23.2527","article-title":"Autoimmune liver diseases in systemic rheumatic diseases","volume":"28","author":"Wang","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205318","article-title":"What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort","volume":"73","author":"Takase","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","article-title":"Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases","volume":"148","author":"Zeng","year":"2024","journal-title":"J Autoimmun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","article-title":"Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases","volume":"36","author":"Samy","year":"2017","journal-title":"Int Rev Immunol"},{"key":"B22","article-title":"Telitacicept, a human recombinant fusion protein targeting and neutralizing B lymphocyte stimulator (BlyS) and a proliferation-Inducing ligand (APRIL), in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate (MTX): A randomized, double-Blind, phase 3 study [abstract","volume":"75","author":"Wang","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","article-title":"Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis","volume":"82","author":"Chen","year":"2016","journal-title":"Br J Clin Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1558059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T07:04:11Z","timestamp":1742281451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1558059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2025.1558059"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1558059","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"article-number":"1558059"}}